690969-16-5

Usage

Uses

Used in Pharmaceutical Industry:
Safinamide Impurity 8 is used as a quality control indicator for ensuring the purity of Safinamide medication. Its detection and quantification are crucial in the pharmaceutical industry to maintain the efficacy and safety of the drug.
Used in Research and Development:
Safinamide Impurity 8 is used as a critical element in the synthesizing and evaluation process for determining the efficacy and safety of the Safinamide medication. It plays a significant role in the development of new pharmaceutical formulations and the improvement of existing ones.

Upstream product

• 66742-57-2 4-(3-fluoro-benzyloxy)-benzaldehyde 
• 623-05-2 (4-hydroxyphenyl)methanol 
• 456-42-8 m-fluorobenzyl chloride 
• 123-08-0 4-hydroxy-benzaldehyde 
• 456-41-7 1-(Bromomethyl)-3-fluorobenzene 
• 456-47-3 3-fluoro-benzenemethanol 
• 28490-56-4 1-fluoro-3-(iodomethyl)benzene 

Downstream Products

• 202825-46-5 safinamide mesylate 
• 133865-89-1 safinamide 
• 1094335-91-7 1-((4-(bromomethyl)phenyloxy)methyl)-3-fluorobenzene 

Relevant academic research and scientific papers

Morpholine amide derivative and application thereof

The invention discloses a morpholine amide derivative and application thereof, and particularly relates to a novel morpholine amide derivative and a pharmaceutical composition containing the compound.The invention also relates to a method for preparing th

PYRROLIDINEAMIDE DERIVATIVES AND USES THEREOF

Provided a pyrrolidineamide compound and a pharmaceutical composition containing this compound which can be used as a MAO-B inhibitor. Also provided methods of preparing this compound and pharmaceutical composition, and their use in the manufacture of a m

Synthesis and anti-cancer activities of aryl benzyl ethers with fluoro substituents

A series of aryl benzyl ethers with fluoro substituents were synthesized and their structures were confirmed by spectral. All the compounds were tested for their cytotoxic activity in vitro against two human tumor cell lines: A549, SGC7901, and most showed cytotoxicity. Compound 10 was the most active in suppressing the growth of both screened cancer cells.

A new enantioselective synthesis of the anti-Parkinson agent safinamide

An alternative highly enantioselective synthesis of the anti-Parkinson agent safinamide from simple, commercially available, starting materials is described. The protocol might also be useful in the synthesis of structural variants of safinamide, such as ralfinamide or related analogues. Georg Thieme Verlag Stuttgart New York.

AN IMPROVED SYNTHESIS OF ANTI-PARKINSON AGENT

The present invention relates to an improved process for synthesis of anti-Parkinson compound of formula (I) from commercially available (R)-benzyl glycidyl ether, wherein the compound obtained has enantiopurity greater than >98%. Formula (I) wherein R1 and R2 are each independently selected from hydrogen or halogen.

Arylalkyl substituted imidazolidinones

New compounds of formula (I), wherein: R1, R2, R3, R4 and R5 are, independently from each other, hydrogen; C1-6alkyl; aryl; heteroaryl and perhaloalkyl, and wherein at least one of R1 and R2 is different from hydrogen; n is 0 or 1; R6 is hydrogen or C1-6

Benzyloxy derivatives as MAOB inhibitors

The invention relates to compounds of the formula and their pharmaceutically acceptable salts wherein R1, R2, R3, R4, R5, n, m, and o are as defined in the specification. The compounds are selective monoamine oxidase β inhibitors and are useful for the treatment and prevention of Alzheimer's disease and senile dementia, as well as other CNS disorders. The invention also relates to processes for preparing such compounds and pharmaceutical compositions containing them.